Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases

被引：0

作者：

Yoshiyuki Mishima

Ryan Balfour Sartor

机构：

[1] Shimane University,Department of Internal Medicine II, Faculty of Medicine

[2] University of North Carolina,Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Crohn’s disease; Ulcerative colitis; Treatment; Bacteria; Live biotherapeutic products;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Altered intestinal microbial composition (dysbiosis) and metabolic products activate aggressive mucosal immune responses that mediate inflammatory bowel diseases (IBD). This dysbiosis impairs the function of regulatory immune cells, which normally promote mucosal homeostasis. Normalizing and maintaining regulatory immune cell function by correcting dysbiosis provides a promising approach to treat IBD patients. However, existing microbe-targeted therapies, including antibiotics, prebiotics, probiotics, and fecal microbial transplantation, provide variable outcomes that are not optimal for current clinical application. This review discusses recent progress in understanding the dysbiosis of IBD and the basis for therapeutic restoration of homeostatic immune function by manipulating an individual patient’s microbiota composition and function. We believe that identifying more precise therapeutic targets and developing appropriate rapid diagnostic tools will guide more effective and safer microbe-based induction and maintenance treatments for IBD patients that can be applied in a personalized manner.

引用

页码：4 / 14

页数：10

共 412 条

[11]

Hand TW(2019)Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases Nature. 569 655-1297

[12]

Nagao-Kitamoto H(2013)Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota Nature. 500 232-446

[13]

Kamada N(2004)T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation J Exp Med. 200 1289-310

[14]

Sartor RB(1999)Regulatory T cells and inflammatory bowel disease Immunol Today. 20 442-487

[15]

Wu GD(2018)Molecular and functional heterogeneity of IL-10-producing CD4 + T cells Nat Commun. 9 5457-230

[16]

Harris KG(2015)Resident bacteria-stimulated IL-10-secreting B cells ameliorate T cell-mediated colitis by inducing Tr-1 cells that require IL-27-signaling Cell Mol Gastroenterol Hepatol. 1 295-662.e4

[17]

Chang EB(2010)Decreased production of interleukin-10 and transforming growth factor-β in Toll-like receptor-activated intestinal B cells in SAMP1/Yit mice Immunology. 131 473-3775

[18]

Kostic AD(2002)Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation Immunity. 16 219-719

[19]

Xavier RJ(2019)Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3 K signaling in IL-10-producing regulatory B cells J Clin Invest. 130 pii: 93820-978

[20]

Gevers D(2011)Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice Gastroenterology. 141 662.e1-324

← 1 2 3 4 5 6 7 8 9 10 →